Table 2.
Standardized incidence ratios for prostate cancer in trans women using hormone treatment
| Follow-up time (years) | Observed cases | Dutch incidence rates (per 100 000 persons, per year) (15) | Expected cases | Standardized incidence ratio (95% confidence interval) | |
|---|---|---|---|---|---|
| Age categories | |||||
| <30 years | 7,190 | 0 | 0 | 0 | — |
| 30-44 years | 14 800 | 0 | 0.32 | 0 | — |
| 45-59 years | 13 429 | 1 | 58.56 | 7 | 0.14 (0.01-0.70) |
| 60-74 years | 4,428 | 4 | 490.54 | 20 | 0.20 (0.06-0.48) |
| >75 years | 535 | 1 | 567.68 | 3 | 0.33 (0.02-1.64) |
| Overall (n = 2,281) | 37 117 | 6 | — | 30 | 0.20 (0.08-0.42) |
| Subgroup analyses | |||||
| Hormone treatment with orchiectomy (n = 1572) | 26 048 | 4 | — | 24 | 0.17 (0.05-0.40) |
| Hormone treatment without orchiectomy (n = 709) | 6796 | 2 | — | 5 | 0.44 (0.07-1.47) |